Bristol Myers, Hengrui join forces in drugmaking alliance worth up to $15.2 billion
BioPharma Dive
The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S.
pharminent
May 12, 2026 (Last updated: May 16, 2026)
BioPharma Dive
The wide-ranging pact involves as many as 13 drugs and marks the latest example of the growing relationship between Chinese pharmaceutical firms and their U.S.